Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cabozantinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET known ✓ | P08581 | 11/20 | 1.00 |
| ▸ | KDR known ✓ | P35968 | 3/20 | 1.00 |
| ▸ | AXL | P30530 | 12/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 4/20 | 1.00 |
| ▸ | MERTK | Q12866 | 3/20 | 1.00 |
| ▸ | FLT1 | P17948 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 2/20 | 1.00 |
| ▸ | AURKA | O14965 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cabozantinib SCHEMBL360795 | 1.00 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29728791 | 1.00 | AXL (1.00) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095042 | 0.99 | AXL (0.98) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18097906 | 0.97 | AXL (0.94) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18095040 | 0.96 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL30692003 | 0.96 | AXL (0.93) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL29195419 | 0.95 | AXL (0.91) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL15872120 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 | |
| SCHEMBL30918289 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 | |
| Cabozantinib SCHEMBL18097904 | 0.95 | AXL (0.90) | AXLMETAURKBMERTKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11912 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144866-A1 | METHODS, DEVICES, AND SYSTEMS FOR PREDICTING TREATMENT RESPONSIVENESS OF CLEAR CELL RENAL CELL CARCINOMA PATIENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-28 | — | — | US | claimed |
| CN-122075677-A | GM-CSF loaded tumor cell vaccine and application thereof in preventing and treating liver cancer | — | 2026-05-26 | — | — | CN | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| US-20260137794-A1 | LIGAND-DRUG CONJUGATE AND USE THEREOF | SYSTIMMUNE INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260137638-A1 | STAT3 INHIBITORS FOR USE IN THE TREATMENT OF NON-VIRAL LIVER CANCER | TYARDI OPERATING CO INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260138953-A1 | CABOZANTINIB COMPOSITIONS AND METHODS OF USE | HANDA ONCOLOGY, LLC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260139320-A1 | StarTrace: A Multiplex Drug Testing Platform for Personalized Medicine | UNIV OF SOUTH CAROLINA (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026105121-A1 | ANTICANCER FORMULATIONS AND USES THEREOF | INTRAGEL THERAPEUTICS LTD. (IL) | 2026-05-21 | — | — | WO | claimed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2022031476-A2 | METHODS AND COMPOSITIONS FOR PROTEASE REPORTER ASSAYS AND MODULATORS | 712 NORTH, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| WO-2022021844-A1 | FILM-COATED TABLET | 江苏万邦生化医药集团有限责任公司 | 2022-02-03 | — | — | WO | claimed |
| CN-113993898-A | Human antibodies that bind RET and methods of use thereof | 瑞泽恩制药公司 | 2022-01-28 | — | — | CN | claimed |
| CN-113975264-A | Method for preventing or treating side effects of tumor therapy | 上海岸阔医药科技有限公司 | 2022-01-28 | — | — | CN | claimed |
| US-20220028512-A1 | SMART DOSING FOR CANCER THERAPY | OptimDosing, LLC | 2022-01-27 | — | — | US | claimed |
| WO-2022020648-A1 | INHIBITORS OF THE ARTEMIN PATHWAY FOR TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022017524-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳晶泰科技有限公司 | 2022-01-27 | — | — | WO | claimed |
| WO-2022020720-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TCR2 Therapeutics Inc. (US) | 2022-01-27 | — | — | WO | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |